Anagrelide is effective in treating patients with hydroxyurea-resistant thrombocytosis in patients with chronic myeloid leukemia

Leukemia

Volumn 19, Issue 1, 2005, Pages 39-43

  Silver, R T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Anagrelide; CML; Thrombocytosis

Indexed keywords

ANAGRELIDE; BUSULFAN; CHLORAMBUCIL; CHLORMETHINE; CYTARABINE; HYDROXYUREA; IMATINIB; INTERFERON; MELPHALAN; PHOSPHORUS 32; THIOTEPA;

ADULT; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ECCHYMOSIS; EPISTAXIS; FEMALE; FLUID RETENTION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; MALE; MYALGIA; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; PHASE 2 CLINICAL TRIAL; POLYCYTHEMIA; PRIORITY JOURNAL; SIDE EFFECT; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOSIS; THROMBOSIS; TREATMENT FAILURE;

EID: 11844263906     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403556     Document Type: Article

References (18)

1. Silver RT. Chronic myeloid leukemia. Curr Opin Oncol 1992; 4: 66-72.
2. Silver RT. Chronic myeloid leukemia. Hematol Oncol Clin North Am 2003; 17: 1159-1173.
3. Ravandi-Kashani F, Schafer AI. Microvascular disturbances, thrombosis, and bleeding in thrombocythemia: current concepts and perspectives. Semin Thromb Hemost 1997; 23: 479-488.
4. Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost 1997; 23: 441-454.
5. van Genderen PJ, Michiels JJ. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera. Semin Thromb Hemost 1997; 23: 357-363.
6. Barbui T, Cortelazzo S, Viero P, Bassan R, Dini E, Semeraro N. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function. Eur J Cancer Clin Oncol 1983; 19: 1593-1599.
7. Fenaux P, Simon M, Caulier MT, Lai JL, Goudemand J, Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549-556.
8. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556-562.
9. Wehmeier A, Daum I, Jamin H, Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann Hematol 1991; 63: 101-106.
10. Colombi M, Radaelli F, Zocchi L, Maiolo AT. Thrombotic and hemorrhagic complications in essential thrombocythemia. A retrospective study of 103 patients. Cancer 1991; 67: 2926-2930.
11. Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myelogenous leukemia and a high platelet count. Blood Cells Mol Dis 1998; 24: 9-13.
12. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992; 92: 69-76.
13. Best PJ, Daoud MS, Pittelkow MR, Petitt RM. Hydroxyurea-induced leg ulceration in 14 patients. Ann Intern Med 1998; 128: 29-32.
14. van Genderen PJ, Leenknegt H, Michiels JJ, Budde U. Acquired von Willebrand disease in myeloproliferative disorders. Leuk Lymphoma 1996; 22 (Suppl 1): 79-82.
15. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler G, Lyne A, Anagrelide Study Group. Anagrelide: Analysis of long term safety and leukemogenic potential in myeloproliferative diseases (MPDs). Blood 2002; 100: 70a (abstr.).
16. Tsimberidou AM, Colburn DE, Welch MA, Cortes JE, Verstovsek S, O'Brien SM et al. Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders. Cancer Chemother Pharmacol 2003; 52: 229-234.
17. Fruchtman S, Pettit RM, Gilbert H. Anagrelide therapy significantly reduces disease related symptoms in patients with myeloproliferafive disorders. Blood 2003; 102: 32a (abstr. ).
18. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003; 348: 994-1004.